Search

Displaying results 1001 - 1010 of 10000 in total
  1. Drug

    Alclofenac

    go.drugbank.com/drugs/DB13167
    ApprovedWithdrawn

    Alclofenac is a non-steroidal anti-inflammatory drug. It was withdrawn from the market in the United Kingdom in 1979.

  2. Drug

    Salmeterol

    go.drugbank.com/drugs/DB00938
    ApprovedInvestigational

    [L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. … Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.

    Mixtures: FLUSARION EH50/250UG/60 PC, FLUSARION EH50/500UG/60 PCCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Drug

    Afatinib

    go.drugbank.com/drugs/DB08916
    ApprovedInvestigational

    Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. … by an FDA-approved test [L2939].

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  4. Drug

    SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)

    go.drugbank.com/drugs/DB18705
    Approved

    [L48902,L48907] Bimervax was issued marketing authorization in the EU in March 2023 for use as a booster dose in patients who have previously received an mRNA COVID-19 vaccine.[L48907] … Bimervax is an adjuvanted non-mRNA COVID-19 vaccine utilizing a SARS-CoV-2 recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer.

  5. Drug

    Cod liver oil

    go.drugbank.com/drugs/DB11321
    ApprovedNutraceuticalVet approved

    Also being a rich source of vitamin A and D, cod liver oil can be taken orally as daily supplements. … It is used as an adjunct treatment and preventative therapy of rickets, osteomalacia and osteoporosis while meeting the consumption criteria.

  6. Drug

    Atosiban

    go.drugbank.com/drugs/DB09059
    ApprovedInvestigational

    Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. … Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor.

  7. Drug

    Plozasiran

    go.drugbank.com/drugs/DB18997
    ApprovedInvestigational

    Plozasiran (ARO-APOC3) is a small interfering RNA (siRNA) that degrades apolipoprotein C-III (apoC-III) mRNA by RNA interference. … Plozasiran contains a covalently linked ligand containing three N-acetylgalactosamine (GalNAc) residues to facilitate delivery to hepatocytes where it works to reduce triglyceride levels.

  8. Drug

    PF-06282999

    go.drugbank.com/drugs/DB11683
    Investigational

    Pf 06282999 is under investigation in clinical trial NCT01626976 (A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects).

  9. Drug

    PF-06260414

    go.drugbank.com/drugs/DB15221
    Investigational

    PF-06260414 is under investigation in clinical trial NCT02070939 (Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects

  10. Drug

    Tofacitinib

    go.drugbank.com/drugs/DB08895
    ApprovedInvestigational

    Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. … Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates